CheckMate 77T Highlights EFS Benefit in Perioperative Nivolumab in Resectable NSCLC
Perioperative nivolumab showed a median event-free survival (EFS) of 40.1 months vs 17.0 months with placebo in resectable non–small cell lung cancer (NSCLC) patients, according to the phase 3 CheckMate 77T study. The study also found significant EFS benefits for patients with and without pathologic complete response (pCR), and higher ctDNA clearance rates with nivolumab.
Reference News
CheckMate 77T Highlights EFS Benefit in Perioperative Nivolumab in Resectable NSCLC
Perioperative nivolumab showed a median event-free survival (EFS) of 40.1 months vs 17.0 months with placebo in resectable non–small cell lung cancer (NSCLC) patients, according to the phase 3 CheckMate 77T study. The study also found significant EFS benefits for patients with and without pathologic complete response (pCR), and higher ctDNA clearance rates with nivolumab.